APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
01 août 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
12 juil. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
06 juil. 2023 08h29 HE
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second...
Ambulatory Polysomnography (PSG) Systems Market to Garner $570.7 Million by 2031 with 6.0% CAGR | Research Dive
14 juin 2023 09h00 HE
|
Research Dive
New York, USA, June 14, 2023 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global ambulatory polysomnography (PSG) systems market is projected to generate a revenue of...
Apnimed to Participate in the 2023 BIO International Convention
23 mai 2023 07h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
21 mai 2023 10h00 HE
|
Apnimed, Inc.
-- New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients -- MARIPOSA Results Support Advancing AD109 to Phase 3 CAMBRIDGE,...
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
17 nov. 2022 08h45 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
North America Sleep Tech Devices Market size to exceed $17 Bn by 2027, says Graphical Research
13 sept. 2022 08h00 HE
|
Graphical Research
Pune, India, Sept. 13, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America sleep tech devices market is forecast to register its name in...
Sleep Tech Devices Market to cross USD 67 billion by 2030, says Global Market Insights Inc.
25 mai 2022 03h17 HE
|
Global Market Insights Inc.
Selbyville, Delaware, May 25, 2022 (GLOBE NEWSWIRE) -- The sleep tech devices market value is expected to reach USD 67 billion by 2030, according to a new research report by Global Market Insights...
Sleep Tech Devices Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
10 mai 2021 06h00 HE
|
Graphical Research
Pune, India, May 10, 2021 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is predicted to show tremendous growth during the forecast period owing to the growing need among...